These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 9390108

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG, Mitchell JD, Lyon M, Moore DH.
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [Abstract] [Full Text] [Related]

  • 3. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.
    Ajroud-Driss S, Saeed M, Khan H, Siddique N, Hung WY, Sufit R, Heller S, Armstrong J, Casey P, Siddique T, Lukas TJ.
    Amyotroph Lateral Scler; 2007 Oct; 8(5):305-9. PubMed ID: 17852022
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.
    Groeneveld GJ, van Kan HJ, Toraño JS, Veldink JH, Guchelaar HJ, Wokke JH, van den Berg LH.
    J Neurol Sci; 2001 Oct 15; 191(1-2):121-5. PubMed ID: 11677002
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term safety of riluzole in amyotrophic lateral sclerosis.
    Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, Meininger V, ALS Study Groups I and II.
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar 15; 3(1):23-9. PubMed ID: 12061945
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Tolerance of riluzole in a phase IIIb clinical trial].
    Lacomblez L, Dib M, Doppler V, Faudet A, Robin V, Salachas F, Bensimon G, Meininger V.
    Therapie; 2002 Mar 15; 57(1):65-71. PubMed ID: 12090150
    [Abstract] [Full Text] [Related]

  • 13. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
    Iłzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M.
    Neurol Sci; 2003 Nov 15; 24(4):290-2. PubMed ID: 14658053
    [Abstract] [Full Text] [Related]

  • 14. Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues.
    Colovic M, Zennaro E, Caccia S.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr 25; 803(2):305-9. PubMed ID: 15063340
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
    van Kan HJ, van den Berg LH, Groeneveld GJ, van der Straaten RJ, van Vught PW, Lie-A-Huen L, Guchelaar HJ.
    Biopharm Drug Dispos; 2008 Apr 25; 29(3):139-44. PubMed ID: 18098330
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov 25; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 19. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M.
    Rev Neurol (Paris); 2006 Jun 25; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.